Beaumont Hospital's department of Urology is conducting a clinical research study for men who have the diagnosis of chronic prostatitis(CP) or chronic pelvic pain syndrome (CPPS). It is a phase II, open-label, 16 week drug (CC-10004, also known as apremilast) study.

Due to the inflammatory nature of CP/CPPS, most prior therapies have focused on targeting the inflammation. CC-10004, in several studies, has shown to be an inhibitor of inflammatory mediators and may decrease the pain experienced from CP/CPPS.

Men, 18 years and older with at least 3 months of symptoms of CP/CPPS (pain in the pelvic area, penis, scrotum or perineum) who are refractory to other therapies (e.g. NSAIDS) may be eligible to participate.

For more information, contact Department of Urology at 248-551-3565.

.........................................................................................
We're sorry you are having to learn about prostatitis, but we're glad you came here, because we think we can help. Please be advised that the Prostatitis Foundation does
not warrant, support, sponsor, endorse, recommend or accept responsibility for any health care provider or any treatment or protocol performed by any heath care provider.

© The Prostatitis Foundation
.........................................................................................